Condition
Malignant Pleural Mesothelioma
Estimated Enrollment: 60
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: ADU-CL-02
Study First Received: August 23, 2012
Last Updated: January 25, 2017
Estimated Primary Completion Date: June 2017
Primary Outcome Measures:
Number of subjects reporting adverse events|Induction of immune response to mesothelin by enzyme-linked immunosorbent spot (ELISPOT) assay|Objective tumor response|Time to progression|Serum mesothelin as correlate of therapeutic response
Sponsors and Collaborators:
Aduro Biotech, Inc.
Website Link: https://ClinicalTrials.gov/show/NCT01675765
